Schizophrenia and depression

Bosanac, Peter; Castle, David

doi:10.5694/mja12.10516

Cited by 25 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suicide-related mortality is higher among subjects recently diagnosed with schizophrenia (≤5 years from diagnosis) [ 46 ]. Symptoms of depression are consistently supported by factors involved in suicidal ideation [ 47 , 48 ]. Even if suicidal ideation may be present in different stages of disease, some differences have been described between the risk of suicide in patients experiencing first episode of psychosis and those with long-term schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study

Corigliano

Comparelli

Mancinelli

et al. 2018

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patients with chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patients with early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-term diagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patients receiving LAI-SGA with 5 or less years of illness duration (n = 10) were compared to those with more than 5 years of illness duration (n = 15). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greater improvement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negative and depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis that LAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies are needed, possibly with larger samples.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study

Corigliano

Comparelli

Mancinelli

et al. 2018

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

show abstract

“…Treatment for depression associated with schizophrenia usually includes various combinations of antipsychotics, mood stabilizers, and antidepressants. However, this approach is controversial and associated with polypharmacy [ 13 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. This combined treatment has both desirable and adverse effects [ 19 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

“…However, this approach is controversial and associated with polypharmacy [13,[16][17][18][19][20][21][22]. This combined treatment has both desirable and adverse effects [19,22].…”

mentioning

confidence: 99%

Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression

Reznik

Syunyakov

Akhmerova

et al. 2022

Consortium Psychiatricum

View full text Add to dashboard Cite

A significant proportion of patients with schizophrenia have depressive symptoms [Lindenmayer, J.-P., 1991; Siris S.G., 2000; Majadas, S., 2012; Miura I., 2021; Liu, 2021]. If in the postpsychotic period depression is found in approximately 20% of patients with schizophrenia, then at the time of exacerbations its frequency increases to 60%, and in total in the anamnesis, especially at the initial stage,. When taking into account the anamnestic data, especially the initial stage, the incidence of depression reaches 80% of patients with schizophrenia suffer from depression [Upthegrove, R., 2017]. Depression is now considered part of the main symptomatology of schizophrenia, added as one of the dimensions in the diagnosis of schizophrenia spectrum disorders [Tandon, R., 2013; Upthegrove, R., 2017; Liu, 2021]. As it turned out, neither the traditional dichotomy of affective disorders and schizophrenia, nor their polarization with the "introduction" of an intermediate diagnostic category - schizoaffective psychosis, nor the now prevailing concept of a wide range of intermediate phenotypes with different representations of psychotic and affective disorders, or a multidimensional phenomenological continuum from conditionally " pure" schizophrenia to the same "pure" bipolar disorder [Reininghaus, U., 2016, 2019; Tamminga, C.A., 2013]. It remains problematic to single out a reference or key feature that makes it possible to distinguish related forms of psychotic and affective disorders. For example, symptoms of depression in patients with schizophrenia are associated with cognitive impairment and in real clinical practice, when assessed at the current moment, are difficult to distinguish from typical negative symptoms of schizophrenia.

show abstract

“…A report of previous studies shows association of depressive symptoms with the current substance used, poor social support and quality of life, family history of depressive disorder, and duration of illness in patient with schizophrenia [ 13 – 15 , 21 ]. During the follow-up period, the medication used to treat schizophrenia, family discord, and socioeconomic problems may enhance the likelihood of developing depression among patients with schizophrenia [ 6 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Depression among Patients with Schizophrenia in Ethiopian Mental Health Hospital: Association with Sociodemographic and Clinical Variables: A Cross-Sectional Study

Tariku

Ali

Misgana

et al. 2021

Depression Research and Treatment

View full text Add to dashboard Cite

Background. Depression is a significant contributor to the global burden of disease and affects all individuals throughout their lifetime. Patients with schizophrenia are frequently attacked by depression during their total illness duration. Presence of comorbid depression in schizophrenia makes the patients more deteriorating and disabling course and poor outcome. Aim of the Study. To determine the prevalence of depression and highlight the associated sociodemographic and clinical factors in patients with schizophrenia in a specialized hospital in Addis Ababa, Ethiopia. Setting. This study was conducted at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Methods. An institutional based cross-sectional study was conducted from May to June 2018. Depression was measured by Calgary Depression Scale for Schizophrenia on 455 samples of patient with schizophrenia and systematic sampling was used to select the study participants. Oslo Social Support Scale and Alcohol, Smoking, and Substance Involvement Screening Test were used to assess social support and substance use factors, respectively. A bivariable and multivariable logistic regression analysis model was performed to control the confounding factors. Odds ratio (OR) with the corresponding 95% confidence interval (95% CI) was determined to evaluate the strength of association. Results. A total of 445 patients responded to the questionnaire, which yields a response rate of 97.8%. The Magnitude of depression among schizophrenia patients was 24.9%. A multivariable logistic regression analysis model showed that being female [AOR 2.00, 95% CI: 1.25-3.18], divorced/widowed [AOR 2.39, 95% CI: 1.04-5.49], current substance use [AOR 1.95, 95% CI: 1.17-3.25], and poor social support [AOR 2.75, 95% CI: 1.35-5.61] were significantly associated with depression in schizophrenia. Conclusion. The magnitude of depression among schizophrenia was 24.9%. Being female, divorced/widowed, current substance use, and poor social support were associated with depression among patients with schizophrenia. Regular screening and prompt management of depressive symptoms among patients with schizophrenia is of particular importance to reduce the burden of the condition.

show abstract

Schizophrenia and depression

Cited by 25 publications

References 30 publications

Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study

Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study

Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression

Depression among Patients with Schizophrenia in Ethiopian Mental Health Hospital: Association with Sociodemographic and Clinical Variables: A Cross-Sectional Study

Contact Info

Product

Resources

About